Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A 6-month Efficacy, Safety and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy

This study has been completed.
Information provided by:
Valeant Pharmaceuticals International, Inc. Identifier:
First received: February 28, 2006
Last updated: July 17, 2011
Last verified: July 2011
The purpose of this study is to determine if the study drug is safe and effective in preventing Hepatic Encephalopathy (HE).

Condition Intervention Phase
Hepatic Encephalopathy
Drug: Rifaximin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy

Resource links provided by NLM:

Further study details as provided by Valeant Pharmaceuticals International, Inc.:

Primary Outcome Measures:
  • Time to treatment failure. [ Time Frame: Entire study ]

Enrollment: 299
Study Start Date: December 2005
Study Completion Date: April 2009
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: placebo Drug: Rifaximin
550 mg tablets BID


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must sign an Informed Consent Form
  • In remission from past hepatic encephalopathy (HE).
  • Appropriate birth control measures
  • More than or equal to 18 years of age.
  • Must be potential for benefit from treatment.
  • Recent prior HE episodes
  • Capable and willing to comply with all study procedures.
  • Subject has personal support available
  • Has a certain Model End Stage Liver Disease (MELD) score
  • Recent TIPS placement or revision

Exclusion Criteria:

  • Significant medical conditions, medical conditions that may impact study participation, or Investigator decision not to include.
  • Allergies to the study drug or similar drugs.
  • Laboratory abnormalities.
  • Recent participation in another clinical trial
  • History of non-compliance
  • Pregnant or at risk of pregnancy, or is lactating.
  • Recent alcohol consumption
  • Active bacterial or viral Infections
  • Bowel issues
  • Active malignancy.
  • On a prohibited medication.
  • Liver transplant expected in near term
  • Lactulose intolerance
  • Subject shows presence of intestinal obstruction or has inflammatory bowel disease.
  • Ongoing or recent GI bleed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00298038

Sponsors and Collaborators
Valeant Pharmaceuticals International, Inc.
Study Director: William Forbes, Pharm D Valeant Pharmaceuticals International, Inc.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Audrey Shaw, Director Clinical, Salix Identifier: NCT00298038     History of Changes
Other Study ID Numbers: RFHE3001
Study First Received: February 28, 2006
Last Updated: July 17, 2011

Additional relevant MeSH terms:
Brain Diseases
Hepatic Encephalopathy
Central Nervous System Diseases
Nervous System Diseases
Liver Failure
Hepatic Insufficiency
Liver Diseases
Digestive System Diseases
Brain Diseases, Metabolic
Metabolic Diseases
Anti-Infective Agents
Gastrointestinal Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Bacterial Agents processed this record on April 28, 2017